News
CVST after COVID-19 vaccine: New data confirm high mortality rate
September 30, 2021
“This is the biggest series, and as an international series, it gives a broader perspective from a larger range of countries.”
News
Study gives bleeding risk estimates for VTE patients on anticoagulants
September 13, 2021
New research provides best available estimates of long-term bleeding risk with different anticoagulants, authors say.
News
Sickle cell disease, trait may up risk for poor COVID outcomes
July 21, 2021
Even those who carry just one copy of the sickle cell gene – the carrier status for sickle cell disease – appeared to be at heightened risk.
News
Early heparin treatment linked to lower COVID-19 mortality
July 15, 2021
Rates of death were significantly lower by almost half in patients who received early heparin than in those who did not.
News
Reversal agents curb DOAC-related bleeding but deaths still high
June 17, 2021
The meta-analysis of more than 4,000 patients also showed thrombotic events were more frequent with andexanet than with 4PCC or idarucizumab.
News
Omics analysis links blood type to COVID-19
May 17, 2021
Within the ABO gene, the research also turned up evidence that blood type O may be protective against COVID-19.
![1]()
News
Trends in the management of pulmonary embolism
May 7, 2021
After completion of primary treatment for patients with unprovoked DVT and/or PE, guidelines suggest indefinite antithrombotic therapy over stopping anticoagulation.
News
AHA guidance on blood clots linked to COVID-19 vaccine
April 30, 2021
“The risk of CVST due to infection with COVID-19 is 8-10 times higher than the risk of CVST after receiving a COVID-19 vaccine.”
News
How some COVID-19 vaccines could cause rare blood clots
April 14, 2021
Six cases of a rare but serious event in patients who got the J&J vaccine are being reviewed.
News
Novel antiplatelet drug: Hope for efficacy without bleeding?
April 12, 2021
A new antiplatelet drug with a completely novel mechanism of action could hold the promise of delivering the holy grail – reducing cardiac events without increasing bleeding.
